β-Lapachone
Code | Size | Price |
---|
TAR-T6407-10mg | 10mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6407-1mL | 1 mL * 10 mM (in DMSO) | £116.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6407-25mg | 25mg | £149.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6407-50mg | 50mg | £227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6407-100mg | 100mg | £329.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6407-200mg | 200mg | £460.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Beta-Lapachone is a specific DNA topoisomerase I inhibitor, and no inhibitory activities against DNA topoisomerase II or ligase.
CAS:
4707-32-8
Formula:
C15H14O3
Molecular Weight:
242.274
Pathway:
Autophagy; Apoptosis; Metabolism; DNA Damage/DNA Repair
Purity:
0.9986
SMILES:
CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O
Target:
IDO; Apoptosis; Topoisomerase; Autophagy
References
Wu L, Ma X, Yang X, et al. Synthesis and biological evaluation of ?-lapachone-monastrol hybrids as potential anticancer agents. European Journal of Medicinal Chemistry. 2020: 112594.
Flick HE, et al. Int J Tryptophan Res. 2013, 6, 35-45.
Li CJ, et al. J Biol Chem. 1993, 268(30), 22463-22468.
Huang X, et al. Cancer Res. 2012, 72(12), 3038-3047.
Wu L, Ma X, Yang X, et al. Synthesis and biological evaluation of ?-lapachone-monastrol hybrids as potential anticancer agents[J]. European Journal of Medicinal Chemistry. 2020: 112594.
Planchon SM, et al. Cancer Res. 1995, 55(17), 3706-3711.
Kung HN, et al. Am J Physiol Cell Physiol. 2008, 295(4), C931-943.
Kim TW, et al. ?-Lapachone enhances Mre11-Rad50-Nbs1 complex expression in cisplatin-induced nephrotoxicity. Pharmacol Rep. 2016 Feb;68(1):27-31.